Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Abstract Background It remains unclear whether hepatitis C virus (HCV)-infected Japanese patients on hemodialysis (HD) have an altered viral response to glecaprevir (GLE) and pibrentasvir (PIB) combination therapy and whether this treatment is safe for this patient group. Therefore, we investigated...

Full description

Bibliographic Details
Main Authors: Yoshiaki Tanaka, Takanori Masaki, Haruki Uojima, Takayasu Ohtake, Tomoaki Fujikawa, Yasuhiro Yamanouchi, Naohisa Wada, Kousuke Kubota, Hisashi Hidaka, Takahide Nakazawa, Akitaka Shibuya, Togo Aoyama, Ji Hyun Sung, Makoto Kako, Shuzo Kobayashi, Yasuo Takeuchi, Wasaburo Koizumi
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Renal Replacement Therapy
Subjects:
Glecaprevir
Pibrentasvir
Chronic kidney disease
Hepatitis C virus
Hemodialysis
Online Access:http://link.springer.com/article/10.1186/s41100-018-0193-4

Similar Items

Similar Items